ASCO GI 2023 | Implementing precision medicine for advanced gastro-esophageal cancers

Nick Pavlakis, PhD, MBBS, FRACP, Royal North Shore Hospital, Sydney, Australia, talks on personalizing treatment for advanced gastro-esophageal cancers. Identifiable biomarkers for gastro-esophageal cancers include claudin, HER2, deficient mismatch repair and fibroblast growth factor receptor (FGFR) to select patients for targeted therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.